Effectiveness of homologous/heterologous booster COVID-19 vaccination schedules against severe illness in general population and clinical subgroups in three European countries.
Riefolo F, Castillo-Cano B, Martín-Pérez M, Messina D, Elbers R, Brink-Kwakkel D, Villalobos F, Ingrasciotta Y, Garcia-Poza P, Swart-Polinder K, Souverein P, Saiz LC, Bissacco CA, Leache L, Tari M, Crisafulli S, Grimaldi L, Vaz T, Gini R, Klungel O and Martín-Merino E
Aten Primaria.2022 Aug; 54(9):102437.doi:10.1016/j.vaccine.2023.10.011Epub 2022 Aug 11. Spanish.PMID:37858451
VAC4EU study to identify risk factors for the development of myocarditis and pericarditis after mRNA1273 vaccination in four European countries: Methodological considerations
L. ZWIERS, B. GOODALE, W. AARTS, D. ESPOSITO, S. ST LAURENT, D. MARTIN, V. URDANETA, M. EMILEBACKER, D. WEIBEL, A. LUPATTELLI, J. ZHAO, L. MAGLANOC, J. DÍEZ-DOMINGO, J. CARRERAS, A. URCHUEGUÍA, E. CORRECHER-MARTÍNEZ, F. VILLALOBOS, M. PALLEJÀ-MILLÁN, E. SEGUNDO, C. BISSACCO, C. FRY, S. LANE, D. ROY, D. GROBBEE and D. ONG
Aten Primaria.2022 Aug; 54(9):102437.doi:Epub 2022 Aug 11. Spanish.PMID: